Literature DB >> 24123431

Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications.

Lorena López-Cerero1, María Dolores Navarro, Mar Bellido, Almudena Martín-Peña, Laura Viñas, José Miguel Cisneros, Sara Louise Gómez-Langley, Herminia Sánchez-Monteseirín, Isabel Morales, Alvaro Pascual, Jesús Rodríguez-Baño.   

Abstract

OBJECTIVES: Escherichia coli belonging to clonal group ST131 has emerged as a significant contributor to infection caused by antibiotic-resistant E. coli worldwide. We investigated the risk factors for infections caused by ST131 E. coli and their clinical implications.
METHODS: One thousand and seventy-seven E. coli isolates were screened for ST131 by molecular methods. Risk factors for ST131 were investigated separately for patients with E. coli producing and not producing extended-spectrum β-lactamases (ESBLs) in the Seville area, Spain. Multivariate analysis using logistic regression was performed. Patients with infections caused by ST131 and non-ST131 isolates were prospectively followed.
RESULTS: Independent risk factors for non-ESBL-producing ST131 were female gender (OR: 1.94; 95% CI: 1.07-3.51), diabetes mellitus (OR: 2.17; 95% CI: 1.29-3.67), bedridden status (OR: 7.75; 95% CI: 0.70-85.07) and exposure to amoxicillin/clavulanate (OR: 2.07; 95% CI: 1.08-3.96) or fluoroquinolones (OR: 2.48; 95% CI: 1.41-4.34). For ESBL-producing ST131, male gender was an independent risk factor (OR: 2.20; 95% CI: 0.94-5.11), while healthcare-related acquisition and exposure to any previous antibiotic were protective (OR: 0.30; 95% CI: 0.13-0.71; and OR: 0.43; 95% CI: 0.19-1.00, respectively). Overall, the severity of sepsis, bacteraemia and mortality were similar among ST131 and non-ST131 groups. The presence of typical factors predisposing to E. coli infection was more frequent in non-ESBL-producing ST131 than in controls (76% versus 57.2%, P = 0.005).
CONCLUSIONS: Previous use of antibiotics selecting for ST131 isolates was the main modifiable risk factor for infections caused by these isolates. Our results also suggest that the clinical virulence of ST131 is not higher than that of other common E. coli causing infections.

Entities:  

Keywords:  antimicrobial resistance; clinical outcomes; extended-spectrum β-lactamases

Mesh:

Substances:

Year:  2013        PMID: 24123431     DOI: 10.1093/jac/dkt405

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

Review 1.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy.

Authors:  Veronika L Tchesnokova; Linda L Ottley; Kyoko Sakamoto; Joshua Fierer; Evgeni Sokurenko; Michael A Liss
Journal:  Urology       Date:  2015-08-20       Impact factor: 2.649

Review 3.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Epidemic Emergence in the United States of Escherichia coli Sequence Type 131-H30 (ST131-H30), 2000 to 2009.

Authors:  James R Johnson; Stephen Porter; Paul Thuras; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  The Role of AcrAB-TolC Efflux Pumps on Quinolone Resistance of E. coli ST131.

Authors:  N Atac; O Kurt-Azap; I Dolapci; A Yesilkaya; O Ergonul; M Gonen; F Can
Journal:  Curr Microbiol       Date:  2018-10-03       Impact factor: 2.188

6.  Isolation and Characterization of Escherichia coli Sequence Type 131 and Other Antimicrobial-Resistant Gram-Negative Bacilli from Clinical Stool Samples from Veterans.

Authors:  Muhanad Mohamed; Connie Clabots; Stephen B Porter; Paul Thuras; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts.

Authors:  James R Johnson; Paul Thuras; Brian D Johnston; Scott J Weissman; Ajit P Limaye; Kim Riddell; Delia Scholes; Veronika Tchesnokova; Evgeni Sokurenko
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

8.  The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing Escherichia coli bacteraemia.

Authors:  Yi-Hui Wu; Ming-Fang Cheng; Chung-Hsu Lai; Hsi-Hsun Lin; Chih-Hsin Hung; Jiun-Ling Wang
Journal:  BMC Infect Dis       Date:  2014-11-07       Impact factor: 3.090

9.  Modelling the epidemiology of Escherichia coli ST131 and the impact of interventions on the community and healthcare centres.

Authors:  A Talaminos; L López-Cerero; J Calvillo; A Pascual; L M Roa; J Rodríguez-Baño
Journal:  Epidemiol Infect       Date:  2016-02-03       Impact factor: 4.434

10.  Diversity of Multi-Drug Resistant Avian Pathogenic Escherichia coli (APEC) Causing Outbreaks of Colibacillosis in Broilers during 2012 in Spain.

Authors:  Marc Solà-Ginés; Karla Cameron-Veas; Ignacio Badiola; Roser Dolz; Natalia Majó; Ghizlane Dahbi; Susana Viso; Azucena Mora; Jorge Blanco; Nuria Piedra-Carrasco; Juan José González-López; Lourdes Migura-Garcia
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.